Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takara Biotech Arm To Create Special Stem Cell Research Unit In Japan

This article was originally published in PharmAsia News

Executive Summary

Takara Holdings' biotechnology subsidiary, Takara Bio, plans to create a special unit to research and develop induced pluripotent stem cells it hopes will lead to cultivating the material. The new unit is to begin work April 1 with a staff of five researchers to draw on Takara Bio's proprietary method of cultivating lymphocytes. The firm said its goal is to use the stem cells to market new technologies for regenerative medicine, with the possibility of also improving gene- and cell-therapy methods. (Click here for more - a subscription may be required

You may also be interested in...



Device Week, 23. October 2020 – Conference Spotlight TCT, HLTH

In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting. 

Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Dr Reddy's Isolates Data Service Centers Among Preventive Actions Responding To Cyberattack

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel